Oncology Imaging

Medical imaging has become integral to cancer care, assessing the stage and location of cancerous tumors. By utilizing powerful imaging modalities including CT, MRI, MRA and PET/CT, oncology imaging radiologists are able to assist referring physicians in the detection and diagnosis of cancer.

Incidental breast calcifications on mammograms linked to much higher risk of cardiovascular disease
These findings may say a lot more about a patient's long-term health than clinicians realized.
New prostate cancer PET imaging agent officially available for commercial use
Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.
FDA grants passage to autonomous, biology-guided radiotherapy
A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.
Disparities in breast cancer detection and care persist, despite a drop in mortality, new ACS report reveals
While Black women have lower incidence of breast cancer diagnosis, their mortality rates are 40% higher than those observed in white women.
PSMA-PET is rapidly changing the standard of care for prostate cancer patients
Adoption of PSMA-PET has been swift because it can significantly improve prostate cancer detection and treatment. SNMMI President Munir Ghesani, MD, explains how.

Breast arterial calcifications (BACs) identified on screening mammograms may help identify women who face a heightened risk of developing cardiovascular disease (CVD), according to a new analysis published in Clinical Imaging.

Incidental breast calcifications on mammograms linked to much higher risk of cardiovascular disease

These findings may say a lot more about a patient's long-term health than clinicians realized.

March 18, 2024

New prostate cancer PET imaging agent officially available for commercial use

Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

June 21, 2023

FDA grants passage to autonomous, biology-guided radiotherapy

A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.

February 3, 2023

Disparities in breast cancer detection and care persist, despite a drop in mortality, new ACS report reveals

While Black women have lower incidence of breast cancer diagnosis, their mortality rates are 40% higher than those observed in white women.

October 3, 2022

Two examples of PSMA-PET scans showing numerous prostate cancer metastases spread throughout the body. Many of these smaller tumors would not have been detected on previous standard-of-care imaging. Photo on left courtesy of SNMMI, right University of Chicago. #PSMAPET

PSMA-PET is rapidly changing the standard of care for prostate cancer patients

Adoption of PSMA-PET has been swift because it can significantly improve prostate cancer detection and treatment. SNMMI President Munir Ghesani, MD, explains how.

August 26, 2022

Munir Ghesani, MD, SNMMI president, explained the impact of PSMA-PET imaging on nuclear image and treatment for prostate cancer.

VIDEO: Advantages of PSMA-PET imaging in prostate cancer care

Munir Ghesani, MD, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and system chief of nuclear medicine at Mount Sinai Health, explains PSMA-PET has seen rapid adoption because it can significantly improve prostate cancer detection and treatment.

August 25, 2022

CT scan showing lung cancer nodules with measurements of each nodule to track growth or regression from treatment. Image courtesy of RSNA

American Indian/Alaskan Native tribes three times more likely to get lung or colorectal cancer

This week presenters at the annual ARRS meeting discussed barriers these populations face when trying access vital cancer screenings.

May 3, 2022

Researchers recently completed an external validation for the Ovarian-Adnexal Reporting and Data System (O-RADS) for classifying lesions as malignant or benign, for which validation had been previously lacking. #ORADS

O-RADS externally validated for differentiating between benign and malignant ovarian lesions

In addition to O-RADS external validation, experts also sought to determine if incorporating acoustic shadowing as a benign finding would improve diagnostic performance.

April 20, 2022

Around the web

Cardiovascular Business

Medicare drops AUC requirement for advanced imaging, ASNC celebrates

"This was an unneeded burden, which was solely adding to the administrative hassles of medicine," said American Society of Nuclear Cardiology President Larry Phillips.

Cardiovascular Business

Cardiology, radiology groups urge insurance provider to rethink imaging policy

SCAI and four other major healthcare organizations signed a joint letter in support of intravascular ultrasound.

Cardiovascular Business

Radiology AI company gains FDA clearance for new CT offerings focused on PE, stroke

The newly approved AI models are designed to improve the detection of pulmonary embolisms and strokes in patients who undergo CT scans.